Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(®) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)

SIMPLE SUMMARY: There are very few systemic treatment options for patients with advanced angiosarcomas. We therefore examined whether combined treatment with paclitaxel and pazopanib was active and well tolerated. However, we did not meet a preplanned interim target of 6/14 patients without progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Pink, Daniel, Andreou, Dimosthenis, Bauer, Sebastian, Brodowicz, Thomas, Kasper, Bernd, Reichardt, Peter, Richter, Stephan, Lindner, Lars H., Szkandera, Joanna, Grünwald, Viktor, Kebenko, Maxim, Kirchner, Marietta, Hohenberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000466/
https://www.ncbi.nlm.nih.gov/pubmed/33799576
http://dx.doi.org/10.3390/cancers13061223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000466/
https://www.ncbi.nlm.nih.gov/pubmed/33799576
http://dx.doi.org/10.3390/cancers13061223

Ejemplares similares